Skip ahead, if you are not interested in science.

Yes, its a bio play. Their T-cell therapy ADP-A2M4 has insane efficacy of response rate of 44% and disease control rate of 94%.

Not convinced? Heres another.

Complete response, 100%. Synovial sarcoma is not even under control. It is completely gone.

Well, it gets better here. Since their T-cell therapy is so successful, why not test on other cancer. They did!

Note the survival time left for gastroesophageal cancer patients (less than 15 months).

Controlled in 8.5 months, 51.52% reduction.

The goal for trial 2 is to expand the T-cell treatment to other cancers. Since the results are very promising, they are trying to target more diseases.

Yep, the institution holds 99.80%. Very interesting.

Oh look, even the people in the company are buying. What a coincidence!

Oh my, so many positions up for hire.

And lastly, my favorite part. It has high growth of 41.9% in 2021. @nathanworden knows I love high revenue growth.

**THE STOCK PRICE

**

It recently sold off from $11 yet institutions kept buying. The current price is at $5.32. Low risk-high reward boiz.

I personally think this is a great stock that comes once in a blue moon. What are your opinions?

@nathanworden take on $ADAP, https://share.commonstock.com/GErfN72Jrcb

Slides: https://d1io3yog0oux5.cloudfront.net/_ca8c151149b3be79feb52f7cf4ade8ba/adaptimmune/db/249/3098/pdf/December+Corporate+Deck_01Dec2020.pdf

Institution holdings: https://www.marketbeat.com/stocks/NASDAQ/ADAP/institutional-ownership/

Insider trades: https://www.marketbeat.com/stocks/NASDAQ/ADAP/insider-trades/

Analyst targets: https://finance.yahoo.com/quote/ADAP/analysis?p=ADAP